home / stock / mor / mor news


MOR News and Press, MorphoSys AG From 01/09/23

Stock Information

Company Name: MorphoSys AG
Stock Symbol: MOR
Market: NASDAQ
Website: morphosys.com

Menu

MOR MOR Quote MOR Short MOR News MOR Articles MOR Message Board
Get MOR Alerts

News, Short Squeeze, Breakout and More Instantly...

MOR - MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxoli...

MOR - MorphoSys AG: Staying On The Sidelines

Summary MorphoSys caps off a year of bad news with the departure of its CFO. With gantenerumab done for now, the key P&L driver will be Monjuvi, a product that had consistently disappointed post-launch. While the stock has been de-rated accordingly, it's hard to underwrite an in...

MOR - MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million) Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Preliminary unaudited financial liability from the collaboration with Incyte of ap...

MOR - MorphoSys AG: Financial Calendar 2023

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023: Publication of Interim Statement / Report Conference Call Year-End Results 2022 March 15, 2023 // 9:00 pm CET (4:00 pm EDT; 8:00 p...

MOR - MorphoSys GAAP EPS of -Euro3.60, revenue of Euro95.8M

MorphoSys press release ( NASDAQ: MOR ): Q3 GAAP EPS of - €3.60. Revenue of €95.8M (+132.5% Y/Y) Updated Full Year 2022 Financial Guidance: Monjuvi U.S. Net Product Sales - Approx. US$ 90M from prior guidance from US$ 90M to 110M. ...

MOR - MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

– Monjuvi ® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 – Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its potential application in a broad array of a...

MOR - MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer's Disease

GRADUATE studies did not meet primary endpoint PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 14, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating g...

MOR - Invitation to MorphoSys' Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022

Conference Call Alert PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 10, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT; 4:00 pm EST). MorphoSys' Management t...

MOR - MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

Presentations - including four oral sessions - feature data supporting the potential benefit of first-line therapy for pelabresib in myelofibrosis and tafasitamab in diffuse large B-cell lymphoma Data add to the growing confidence in MorphoSys' pipeline and its pivotal trials BOSTON...

MOR - MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR Symposium PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that preliminary results from th...

Previous 10 Next 10